Savvy Advisors Inc. Buys 9,658 Shares of Abbott Laboratories $ABT

Savvy Advisors Inc. grew its stake in shares of Abbott Laboratories (NYSE:ABT) by 47.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 30,120 shares of the healthcare product maker’s stock after buying an additional 9,658 shares during the quarter. Savvy Advisors Inc.’s holdings in Abbott Laboratories were worth $3,774,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Brighton Jones LLC lifted its stake in Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after purchasing an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC increased its position in shares of Abbott Laboratories by 3.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after purchasing an additional 162 shares during the last quarter. United Bank raised its holdings in shares of Abbott Laboratories by 7.4% during the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after buying an additional 2,001 shares in the last quarter. Edgestream Partners L.P. purchased a new position in shares of Abbott Laboratories during the 2nd quarter valued at about $404,000. Finally, Brown Advisory Inc. lifted its position in Abbott Laboratories by 0.4% in the 2nd quarter. Brown Advisory Inc. now owns 520,211 shares of the healthcare product maker’s stock worth $70,754,000 after buying an additional 2,061 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Abbott Laboratories

In related news, EVP Mary K. Moreland sold 613 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the sale, the executive vice president owned 104,291 shares of the company’s stock, valued at $12,053,953.78. This trade represents a 0.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Eric Shroff sold 709 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $81,946.22. Following the completion of the transaction, the senior vice president directly owned 39,164 shares in the company, valued at $4,526,575.12. This trade represents a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 3,055 shares of company stock worth $353,097 in the last 90 days. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $102.84 on Friday. The stock’s 50 day moving average is $109.48 and its 200 day moving average is $121.03. The company has a market capitalization of $179.11 billion, a P/E ratio of 27.65, a PEG ratio of 1.64 and a beta of 0.79. Abbott Laboratories has a twelve month low of $100.88 and a twelve month high of $139.06. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same period in the previous year, the company posted $1.34 earnings per share. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is 67.74%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Barclays cut their price objective on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research note on Monday, February 2nd. Argus cut their price target on shares of Abbott Laboratories from $150.00 to $140.00 in a research report on Tuesday, January 27th. Freedom Capital raised Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 29th. Piper Sandler decreased their target price on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research note on Friday, January 23rd. Finally, Sanford C. Bernstein reduced their price target on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $135.68.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.